Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 18

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 18
---
 adversely affect our business, financial condition, operating results,
and prospects. Our business strategy heavily depends on our ability to commercialize our clinical assets and our ability to enter into
license agreements relating to such clinical assets is critical to the success of our operations

We
may choose not to continue developing or commercializing any of our clinical assets at any time during development or after approval,
which would reduce or eliminate our potential return on investment for those clinical assets.

We
may decide to discontinue the development of any of our clinical assets or not to continue commercializing one or more of our approved
clinical assets for a variety of reasons, including the appearance of new technologies that make a product obsolete, competition from
a competing product, or changes in or failure to comply with applicable regulatory requirements at any time. If we terminate a program
in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity
to have allocated those resources to potentially more productive uses.

If
we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize
our clinical assets or otherwise implement our business plan.

Our
ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified
managerial, scientific, medical, sales, marketing, and other personnel. We are highly dependent on our management, including our Chief
Executive Officer, David Tapolczay. The loss of the services of any of these individuals could impede, delay, or prevent the successful
development of our product pipeline, completion of our planned clinical trials, commercialization of our clinical assets, or in-licensing
or acquisition of new assets and could negatively impact our ability to successfully implement our business plan. If we lose the services
of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be
harmed as a result. We do not maintain “key man” insurance policies on the lives of these individuals or the lives of any
of our other employees. In order to retain valuable employees, in addition to salary and cash incentives, we provide stock options that
vest over time.

40

We
might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for
qualified personnel among biotechnology, pharmaceutical, and other businesses. We could have difficulty attracting experienced personnel
to the Company and may be required